(Continuation news of SQURPHARMA): The overall impact was a good 11% growth in gross profit which has contributed towards earning a good EPS. Additionally, our prudent investment decision has paid off quite well. We have been able to earn a significant amount of other income in form of dividend, gain on bonds and marketable securities, interest etc. (please see note 21 of standalone annual report) (cont. 2)